The 4 biggest hiring mistakes biopharma executives keep making
The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and...
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug...
Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that would have made GLP-1 drugs more affordable to patients.
In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for resubmission remains uncertain.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Big news: I’ve convinced at least...
The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, the mega-blockbuster cancer drug Keytruda.
Fluorescent probes have reshaped how biologists study living systems, making it possible to watch viruses invade cells, follow the cell’s internal waste‑disposal machinery, and track the...
Vani Hari has 2.3 million followers on Instagram, and about as many ideas for healthy food swaps. An entrepreneur and influential food activist in the Make...
As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is reducing everyday burdens.